ARS Pharmaceuticals, Inc.
SPRY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$51,151 | -$44,883 | -$33,940 | $49,934 |
| Dep. & Amort. | $2,352 | $279 | -$1,681 | -$1,515 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $5,689 | $5,371 | $5,298 | $4,263 |
| Change in WC | -$1,070 | -$1,052 | -$10,419 | -$10,678 |
| Other Non-Cash | -$2,867 | $693 | $0 | $0 |
| Operating Cash Flow | -$47,047 | -$39,592 | -$40,742 | $42,004 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$197 | -$51 | -$91 | -$302 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$127,424 | -$31,378 | -$34,345 | -$163,458 |
| Inv. Sales/Matur. | $88,500 | $80,000 | $63,500 | $67,000 |
| Other Inv. Act. | -$5,860 | $0 | $0 | -$5,000 |
| Investing Cash Flow | -$44,981 | $48,571 | $29,064 | -$101,760 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $96,989 | $0 | $0 | $0 |
| Stock Issued | $479 | $2,697 | $725 | $1,533 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $2,577 | $0 | $0 | $69,383 |
| Financing Cash Flow | $100,045 | $2,697 | $725 | $70,916 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $8,017 | $11,676 | -$10,953 | $11,160 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $51,540 | $39,864 | $50,817 | $39,657 |
| End Cash | $59,557 | $51,540 | $39,864 | $50,817 |
| Free Cash Flow | -$47,244 | -$39,643 | -$40,833 | $41,702 |